1

2
Tarran Jones
Masayuki Tsuchiya, Koh Sato, Mary Margaret Bendig, Steven Tarran Jones, Jose William Saldanha: Reshaped human antibody to human interleukin-6 receptor. Chugai Seiyaku Kabushiki Kaisha, Foley & Lardner, January 20, 2009: US07479543 (96 worldwide citation)

A reshaped human antibody to the human IL-6R, comprising: (A) an L chain comprising, (1) a human L chain C region, and (2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRs) of a momoclonal antibody to the IL-6 receptor ...


3

4
Tarran Jones
Neil I Goldstein, Nicholas A Giorgio, Steven Tarran Jones, Jose William Saldanha: Humanized anti-EGF receptor monoclonal antibody. ImClone Systems Incorporated, Kenyon & Kenyon, June 13, 2006: US07060808 (55 worldwide citation)

A nucleic acid is provided which encodes a humanized antibody or fragment thereof, which encodes a protein which binds to human EGF-receptor. Monoclonal antibody 225 is the complementary determining region (CDR) donor.


5
Guriq Basi, Jose William Saldanha: Humanized antibodies that recognize beta amyloid peptide. Neuralab, Wyeth, Lahive & Cockfield, Amy E Mandragouras, Debra J Milasincic, February 20, 2007: US07179892 (72 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.


6
Guriq Basi, Jose William Saldanha: Humanized antibodies that recognize beta amyloid peptide. Wyeth, Neuralab, Lahive & Cockfield, Amy E Mandragouras Esq, Debra J Milasincic Esq, March 13, 2007: US07189819 (48 worldwide citation)

The invention provides improves agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.


7
Guriq Basi, Jose William Saldanha: Humanized antibodies that recognize beta amyloid peptide. Elan Pharma International, Wyeth, Townsend and Townsend and Crew, September 1, 2009: US07582733 (24 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.


8
John Edward Park, Pilar Garin Chesa, Uwe Bamberger, Wolfgang J Rettig, Olivier Lèger, Jose William Saldanha: FAP&agr;-specific antibody with improved producibility. Boehringer Ingelheim International, Sterne Kessler Goldstei & Fox P L L C, September 24, 2002: US06455677 (15 worldwide citation)

Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purpose ...


9
Guriq Basi, Jose William Saldanha, Dale B Schenk: Humanized antibodies that recognize β-amyloid peptide. Janssen Alzheimer Immunotherapy, Wyeth, Townsend and Townsend and Crew, April 20, 2010: US07700751 (11 worldwide citation)

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.


10
Michael Karpusas, Paul D Lyne, Jose William Saldanha, Ellen A Garber: Antibodies to VLA-1. Biogen Idec MA, Lando & Anastasi, March 22, 2011: US07910099 (6 worldwide citation)

Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structur ...